On October 22, 2020 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, reported that its Board of Directors declared a quarterly dividend of $0.225 per share, payable on December 15, 2020 to shareholders of record on November 27, 2020 (Press release, Perrigo Company, OCT 22, 2020, View Source [SID1234568827]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 22, 2020 Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, reported that members of the Company’s immuno-oncology team will provide an overview of the company’s early-stage immuno-oncology research, specifically the AL008 development program, at two upcoming virtual scientific meetings (Press release, Alector, OCT 22, 2020, View Source [SID1234568825]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AL008 is a novel, investigational, antibody product candidate targeting the CD47-SIRP-alpha (SIRPα) pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. AL008 is a potential best-in-class SIRPα inhibitor with a unique dual mechanism of action that non‑competitively antagonizes the CD47- SIRPα pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (a "don’t eat me signal") while also engaging and activating Fcγ gamma receptor (FcγgammaR) to promote immuno-stimulatory pathways that drive anti-tumor immunity.

The virtual scientific meetings include the:

Macrophage-Directed Therapies Summit
Date and Time: Wednesday, October 28, 2020 at 10:30 a.m. EST
Presentation: A Novel Approach to Targeting the SIRPα Checkpoint Pathway and FcγgammaR Signaling
Presenter: Spencer Liang, Ph.D., senior director and head of immuno-oncology
CD47|SIRPα Summit
Date and Time: Wednesday, November 4, 2020 at 4:30 p.m. EST
Panel: What are the Predictive Biomarkers Arising When Targeting CD47|SIRPα Pathways?
Presenter: Spencer Liang, Ph.D., senior director and head of immuno-oncology

Date and Time: Thursday, November 5, 2020 at 11:35 a.m. EST
Presentation: An Insight into Alector’s Novel Approach to Drive Anti-Tumor Immunity Targeting CD47|SIRPα Pathways
Presenter: Andrew Picentic, Ph.D., senior staff scientist and group leader

Date and Time: Thursday, November 5, 2020 at 11:35 a.m. EST
Panel: How Can We Manage Toxicity and Improve Clinical Practice in Targeting CD47|SIRPα Pathways?
Presenter: Daniel Maslyar, M.D., vice president of clinical development, oncology
"We are pleased to be highlighting the progress of our early-stage immuno-oncology programs at two notable research forums," said Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector. "Despite the tremendous progress that has been made in the treatment landscape for cancer in the last 20 years, the need for additional, effective treatment options remains. Alector is leveraging its knowledge of the innate immune system, with the goal of developing novel, first-in-class therapies for patients who need new treatments."

On October 22, 2020 Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, reported the presentation of new data on the company’s novel hematopoietic progenitor kinase 1 (HPK1) inhibitors at upcoming scientific conferences (Press release, Nimbus Therapeutics, OCT 22, 2020, View Source [SID1234568805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the 32nd EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium, from October 24-25, 2020, Nimbus will present new in vivo data, including target engagement, tumor growth inhibition, and pharmacodynamics in two mouse syngeneic tumor models (CT26 and B16/F10).

Further, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting, from November 9-14, 2020, Nimbus will present new data on in vitro pharmacology and mechanism of action of the HPK1 inhibitors, including effects on T cells, B cells, dendritic cells and antigen presentation.

"Building on the data we presented at AACR (Free AACR Whitepaper) earlier this year, we’re pleased to share these new results which provide further support for the anti-tumor immune activity of our small-molecule HPK1 inhibitors," said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. "We are progressing towards initiation of IND-enabling studies in the near future, with plans to embark upon first-in-human studies of this novel therapeutic in 2021."

Details of the presentations are as follows:

EORTC 2020: Pre-recorded presentation with live Q&A

Title: "A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model"
Presentation Number: PD-046
Date & Time: Sun., Oct. 25, 2:50 p.m. CET (9:50 a.m. ET)
SITC 2020: Live presentation

Title: "A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model"
Poster Number: 685
Dates & Times: Weds., Nov. 11, 5:15 p.m. ET; Fri., Nov. 13, 4:40 p.m. ET

On October 22, 2020 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that it will webcast its Quarterly Update Conference Call for the third quarter 2020 on Monday, November 2 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call (Press release, Halozyme, OCT 22, 2020, View Source [SID1234568804]). On the same date, Halozyme will release financial results for the third quarter ended September 30, 2020, following the close of trading.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To register for this conference call, please use this link: View Source After registering, you will receive an email confirmation that includes dial in details and unique conference call codes for entry. Registration is open through the live call. However, to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

The call will be webcast live through the "Investors" section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit the Investors page of www.halozyme.com approximately 15 minutes prior to the call to register, download and install any necessary audio software. A telephone replay will be available for two weeks after the call by dialing (800) 585-8367 (domestic callers) or (416) 621-4642 (international callers) using replay ID number 7767139.

On October 22, 2020 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that members of management will participate in the Virtual Investor KOL Roundtable on Wednesday, October 28, 2020 at 4:00 PM ET (Press release, Navidea Biopharmaceuticals, OCT 22, 2020, View Source [SID1234568802]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participating in the KOL Roundtable discussion will be Jed Latkin, Navidea’s Chief Executive Officer and Michael Rosol, Ph.D., Chief Medical Officer of Navidea. Joining the Navidea management team for the discussion will be Jonathan Graf, MD. Dr. Graf is Professor in the Department of Medicine at the University of California San Francisco (UCSF) in the division of rheumatology at Zuckerberg San Francisco General. He is board certified in rheumatology, receiving his MD degree from the University of Pennsylvania and completing his residency and fellowship training at the UCSF School of Medicine. He has been a practicing rheumatologist for nearly 20 years and co-founded the UCSF rheumatoid arthritis (RA) cohort in 2006. He is co-author on numerous publications in the field of rheumatology and has been an investigator on multiple clinical trials related to rheumatoid arthritis. He currently receives research support from Navidea as one of the lead investigators for the NAV3-31 trial in RA, and he has been involved in the design and execution of this and other clinical trials of Tilmanocept in RA.

A live video webcast of the KOL Roundtable will be available on the IR Calendar page of the Investors section of the Company’s website (www.navidea.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

In addition to the KOL roundtable discussion, members of the management team will be available for one-on-one meetings with qualified members of the investment community. To schedule a one-on-one call with management, please submit a request through the conference website virtualinvestorco.com, or contact the conference at [email protected]. For more information about the event, please visit virtualinvestorco.com.